Tumor stroma-derived insulin-like growth factor 1(IGF-1) and insulin-like growth factor binding protein (IGFBP) signaling have the potential to be novel targets for cancer therapy or adjuvant treatment, but these therapies have so far failed to yield significant efficacy [48]. The gene discussed is IGF1; the disease is cancer.